Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
← catalyst calendarSponsored by Quoin Pharmaceuticals (industry) · QNRX — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2025 | estimated | When the study began enrolling |
| Primary completion | 2026-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Netherton Syndrome
Intervention
- Drug: QRX003, 4% Lotion
Primary outcome
what the primary-completion date above is the date OFProportion of subjects with 1-point reduction on IGA
measured Up to week 16
Permalink · QNRX's whole pipeline · Catalyst calendar · Every registered study · What changed